Digital Biomarkers and Neurodegenerative Disorders

Neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease are on the rise throughout the world as the population ages. These diseases represent a major threat to human health and have diverse effects, with some causing memory/cognitive impairments and others hindering patients’ ability to speak, breathe and/or move. Current treatments and medications are inadequate for treating these disorders and new, effective therapies are sorely needed.

Digital devices are helping researchers forge new paths to better understand and treat neurological disorders. Join this webinar to learn about the types of digital devices that are currently available as well as the key clinical insights that can be gained from their use.

Referencing a few examples of current studies underway, the speakers will share best practices for deploying digital devices into clinical trials of neurological disorders and the insights that continuous collection of physiological data enables. Finally, the speakers will discuss the current status of biomarkers in neurodegenerative disease research and the implications of digital biomarker data in clinical endpoints.

Speakers

Ray Dorsey, MD, David M. Levy Professor of Neurology and Director of the Center for Health + Technology, University of Rochester

Dr. Ray Dorsey and his colleagues seek to enable anyone anywhere to receive care, participate in research and benefit from therapeutic advances. They have written Ending Parkinson’s Disease, a book that provides a prescription for ending this debilitating condition. Dorsey previously directed the movement disorders division and neurology telemedicine at Johns Hopkins and worked as a consultant for McKinsey & Company. His research has been published in leading medical, neurology and economic journals and has been featured on National Public Radio, in the New York Times and in the Wall Street Journal. In 2015, the White House recognized him as a “Champion for Change” for Parkinson’s disease.

Message Presenter

Mark Matson, MBA, Vice President, Sales and Licensing, MC10 Inc.

Mark Matson is a research professional with 25 years in drug development with long stints at Pfizer, MannKind Corp and IQVIA. Over his career, Matson has been involved in all aspects of drug development, including clinical and non-clinical development, portfolio and program management, formulation development, finance, licensing and sales. Matson holds an Honors Degree in Molecular and Cellular Biology from the University of Connecticut, an MBA from Rensselaer Polytechnic Institute and numerous graduate certificates from Harvard Business School.

Message Presenter

Glen Frick, MD, PhD, FAAP, Senior Medical Director, Neuroscience, Ophthalmology & Women’s Health, Covance

Glen Frick is a Fellowship-Trained Pharmacologist and Board-Certified Pediatrician with nearly 20 years of extensive Phase I-IV clinical trial experience. Frick has held key leadership roles within the pharmaceutical industry, including GlaxoSmithKline, Wyeth/Pfizer, Shire and Endo. He has conducted clinical and translational medicine studies in Neurodegeneration, Respiratory, Inflammation, Psychiatry, Pain and Dermatology. Frick completed an MD/PhD program at SUNY-Downstate Medical Center, obtaining his PhD in Developmental Neural & Behavioral Science. He served as VP of Clinical Development & Operations at Endo Pharmaceuticals and was Chief Medical Officer at Clene Nanomedicine, a start-up biotech in Salt Lake City, Utah prior to joining Covance in the Neurology Group.

Message Presenter